Back to results
US 2026/0007779 A1Published application
Ct contrast agent for detection of cachexia
AssigneeUniversite De Geneve
InventorsAndrej BABIC, Nathalie STRANSKY-HEILKRON
Life of this patent
Estimating the term…
Abstract
The invention relates to an iodinated CT contrast agent for non-invasive diagnosis of cachexia. This is possible by superior resolution of CT combined with CT contrast agent specific for the brown and/or beige adipose tissue (BAT).
Claims15
1-17. (canceled)
A method of diagnosing a cancer in a subject, the method comprises the steps of:
- a) orally administering a peroral contrast agent to the subject, the peroral contrast agent comprising an iodinated fatty acid, ester, or combinations thereof with 16 to 18 carbon atoms
- having the following formula I:
- wherein:
- n=14−16;
- R1 is, at each occurrence, independently H or I, provided that when a number of iodine atoms is 1 to 6, the iodine atoms are not geminal or vicinal;
- and
- R2 is H, unsaturated alkyls, saturated alkyls, linear alkyls, branched alkyls, alkoxyalkyl, hydroxyalkoxyalkyl, polyhydroxyalkyl, or hydroxy poly alkylencoxyalkyl;
- b) obtaining an in vivo image of brown and/or beige adipose tissue (BAT) in the subject with Computed Tomography (CT);
- and
- c) comparing the obtained in vivo image to a CT scan of normal subject, wherein a diagnosis of a cancer is performed by:
- i) establishing positive or increased enhancement of BAT and/or beige adipose tissue;
- or
- ii) detecting a white adipose tissue (WAT) browning and/or BAT activity in the subject, wherein the cancer is selected from the group consisting of:
- lung cancer, pancreatic cancer, liver cancer, colon cancer, gastric cancer, prostate cancer, breast cancer, esophageal, head and neck, ovarian cancer, cervical cancer, and sarcoma.
11 more elements
(canceled)
(canceled)
Dependencies are inferred from the claim text.